Zila Signs Agreement to Expand Distribution of Peridex(R) into Greece
January 24 2006 - 9:14AM
Business Wire
Zila, Inc., (Nasdaq: ZILA) announced that its wholly owned
subsidiary, Zila Pharmaceuticals, Inc., manufacturer and marketer
of Peridex, has established an exclusive supply agreement with Aven
Dental S.A of Athens, Greece for the distribution of Peridex in
Greece. "We are very pleased to have established a presence in
Greece and look forward to expanding Peridex throughout the
European Union," stated Douglas D. Burkett, Ph.D., Chairman, Chief
Executive Officer and President of Zila. "We are excited about this
opportunity to develop and grow the international business for
Peridex and Zila Pharmaceuticals." About Peridex(R) Peridex is the
leading brand-name prescription mouth rinse for the treatment of
gingivitis. Peridex reduces the redness, swelling and bleeding of
gums caused by gingivitis. With a pleasant herbal mint taste,
Peridex continues to work even after rinsing because one third of
its active ingredient -- chlorhexidine gluconate -- binds to oral
surfaces and is slowly released to extend its effectiveness for up
to 12 hours. Peridex is the first prescription oral rinse to
receive the ADA Seal of Acceptance for the treatment of gingivitis.
Peridex is endorsed by leading dentists and dispensed by leading
pharmacies throughout the United States and Canada. Visit
www.peridex.net for more information about Peridex and Zila
Pharmaceuticals. About Aven Dental S.A. Aven Dental S.A. was
founded in 1979 to provide leading dental products to the Greek
market. Aven currently represents many well known companies and
brands including OralB/Rembrandt, Parkell, and Orascoptic. In 2000,
Aven Dental founded a subsidiary company to represent and market
its dental products in Crete. Since 2001, Aven Dental has published
the newspaper "Aven Dental Family" with information, techniques and
informative articles for the Greek professional dental market.
About Zila, Inc. Zila, Inc., headquartered in Phoenix, is an
innovator in preventative healthcare technologies and products,
focusing on enhanced body defense and the detection of pre-disease
states. Zila has three business units: -- Zila Biotechnology, a
research, development and licensing business specializing in
pre-cancer/cancer detection through its patented Zila(R) Tolonium
Chloride and OraTest(R) technologies. -- Zila Pharmaceuticals,
marketer of products to promote oral health and prevent oral
disease, including ViziLite(R) Plus oral examination kits and
Peridex(R) prescription periodontal rinse. -- Zila Nutraceuticals,
manufacturer and marketer of Ester-C(R) and Ester-E(R), branded,
highly effective forms of Advanced Protection vitamins C and E. --
For more information about Zila, visit www.zila.com. This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements
are based largely on Zila's expectations or forecasts of future
events, can be affected by inaccurate assumptions and are subject
to various business risks and known and unknown uncertainties, a
number of which are beyond the Company's control. Therefore, actual
results could differ materially from the forward-looking statements
contained herein. A wide variety of factors could cause or
contribute to such differences and could adversely impact revenues,
profitability, cash flows and capital needs. There can be no
assurance that the forward-looking statements contained in this
press release will, in fact, transpire or prove to be accurate. For
a more detailed description of these and other cautionary factors
that may affect Zila's future results, please refer to Zila's Form
10-K for its fiscal year ended July 31, 2005.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024